Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 13/20 | 0.76 |
| ▸ | ACACA | Q13085 | 13/20 | 0.76 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | PRKACA | P17612 | 1/20 | 0.33 |
| ▸ | PRKACG | P22612 | 1/20 | 0.33 |
| ▸ | PRKACB | P22694 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | WEE1 | P30291 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14689442 | 0.90 | ACACB (0.72) | ACACBACACATHRBPRKACAPRKACG | |
| SCHEMBL12457588 | 0.90 | ACACB (0.72) | ACACBACACATHRBPRKACAPRKACG | |
| SCHEMBL14689443 | 0.90 | ACACB (0.72) | ACACBACACATHRBPRKACAPRKACG | |
| SCHEMBL13174171 | 0.87 | ACACB (0.59) | ACACBACACATHRBFFAR4WEE1 | |
| SCHEMBL12841315 | 0.87 | ACACB (0.59) | ACACBACACATHRBFFAR4WEE1 | |
| SCHEMBL12452262 | 0.87 | ACACB (0.59) | ACACBACACATHRBFFAR4WEE1 | |
| SCHEMBL13596570 | 0.87 | ACACB (0.59) | ACACBACACATHRBFFAR4WEE1 | |
| SCHEMBL12458444 | 0.87 | ACACB (1.00) | ACACBACACAPRKACA | |
| SCHEMBL14689551 | 0.87 | ACACB (1.00) | ACACBACACAPRKACA | |
| SCHEMBL2349261 | 0.87 | ACACB (1.00) | ACACBACACAPRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1943218-B1 | ALKOXYALKYL SPIROCYCLIC TETRAMIC ACIDS AND TETRONIC ACIDS | BAYER IP GMBH (DE) | 2015-05-06 | — | — | EP | disclosed |
| US-8138119-B2 | Alkoxyalkyl spirocyclic tetramic acids and tetronic acids | BAYER CROPSCIENCE AG (DE) | 2012-03-20 | — | — | US | disclosed |
| US-20090215624-A1 | Alkoxyalkyl Spirocyclic Tetramic Acids and Tetronic Acids | BAYER CROPSCIENCE AG (DE) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215624-A1 | Alkoxyalkyl Spirocyclic Tetramic Acids and Tetronic Acids | DDT, TBCD, TBCA | ACACB 1097/4885ACACA 896/4885THRB 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.